◇ Physician-supervised protocols◇ Third-party tested · COA on every lot◇ 99%+ verified purity◇ Cold-chain shipping in 48 hours◇ Licensed in 43 states ◇ Physician-supervised protocols◇ Third-party tested · COA on every lot◇ 99%+ verified purity◇ Cold-chain shipping in 48 hours◇ Licensed in 43 states
Home / Formulary / Retatrutide
Back to formulary
Retatrutide — LORIUM lyophilised vial LORIUM · 10 mg LYOPHILISED VIAL
Third-party tested · COA included with every lot
Metabolic ● In stockPrescription required

Retatrutide

Triple GLP-1/GIP/glucagon agonist · GLP-1 R

GLP-1 R represents the absolute pinnacle of metabolic science: a breakthrough triple-receptor agonist engineered to simultaneously target GLP-1, GIP, and glucagon pathways. This multi-targeted synergy unlocks notable fat oxidation, elevated energy expenditure, and comprehensive metabolic reprogramming.

$379 / month · 10 mg
Request through a provider Start intake to prescribe
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. It is dispensed only pursuant to a valid prescription following evaluation by a licensed provider.

Researched effects

Effects observed in the cited literature. Individual results are not guaranteed. Statements have not been evaluated by the FDA.

Maximum Weight Loss

Promotes up to an notable 24% reduction in total body weight.

Glycemic Precision

Lowers HbA1c by up to 2.2% while restoring healthy insulin sensitivity.

Thermogenic Activation

Amplifies energy expenditure and targets fatty acid oxidation.

Advanced Satiety

Dual neural pathways achieve strong appetite control and reduced intake.

Visceral Fat Targeting

Drives preferential loss of deep visceral fat while preserving lean muscle.

Triple Action

Co-agonist targeting GLP-1, GIP, and Glucagon receptors.

Cardiovascular Defense

Significantly lowers triglycerides and clinical systolic blood pressure.

Specifications

ClassTriple GLP-1/GIP/glucagon agonist
CAS number2381089-83-2
Molar mass4731.33 g/mol
Available sizes10 mg, 20 mg
AdministrationPremium once-weekly subcutaneous dosing protocol.
CategoryMetabolic
View a sample certificate of analysis →

Clinical references

  1. Jastreboff, A.M., et al. (2025). Efficacy and safety of retatrutide, a GLP-1, GIP, and glucagon receptor agonist for weight management in adults with obesity. Obesity Medicine, 15, 100523. DOI.
  2. Enebo, L.B., et al. (2023). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Obesity, 31(2), 296-308. DOI.
  3. Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, phase 2 trial. The Lancet, 402(10401), 529-544. DOI
Related

More in Metabolic

View all →
Metabolic AOD-9604
AOD-9604 vial

AOD-9604

GH fragment

A structurally modified fragment of human growth hormone designed to target adipose tissue metabolism and enhance fat breakdown.

from $149/mo
Metabolic GLP-1 S
Semaglutide vial

Semaglutide

GLP-1 receptor agonist

A long-acting GLP-1 receptor agonist with 94% homology to natural human GLP-1, delivering sustained metabolic control, appetite suppression, and multi-organ protection.

from $229/mo
Metabolic TESAMORELIN
Tesamorelin vial

Tesamorelin

GHRH analogue

A structurally optimized GHRH analogue that stimulates natural pulsatile growth hormone secretion to reduce deep visceral fat and optimize lipid biomarkers.

from $189/mo